Decitabine (Dacogen®)

Assessment Status Rapid review complete
Drug Decitabine
Brand Dacogen®
Indication For AML in patients who are >65yrs who are not candidates for standard induction therapy
Assessment Process
Rapid review commissioned 08/11/2012
Rapid review completed 13/12/2012
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended

05/12/2013  Following additional commercial discussions the HSE has approved reimbursement of Decitabine (Dacogen®) in the hospital setting.